$0.46
9.49%
Nasdaq, Mon, Dec 30 2024
ISIN
US00534A1025
Symbol
ADGI

Adagio Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Adagio Therapeutics Inc Classifications & Recommendation:

Buy
75%
Hold
25%

Adagio Therapeutics Inc Price Target

Target Price $5.89
Price $0.46
Potential
Number of Estimates 4
4 Analysts have issued a price target Adagio Therapeutics Inc 2025 . The average Adagio Therapeutics Inc target price is $5.89. This is higher than the current stock price. The highest price target is
$10.00 2,066.38%
register free of charge
, the lowest is .
A rating was issued by 4 analysts: 3 Analysts recommend Adagio Therapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Adagio Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Adagio Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.00 25.92

4 Analysts have issued a sales forecast Adagio Therapeutics Inc 2024 . The average Adagio Therapeutics Inc sales estimate is

$25.9m
Unlock
. This is
124.20% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$28.6m 147.40%
Unlock
, the lowest is
$21.6m 86.85%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $0.0
2025
$142m 449.12%
Unlock
2026
$316m 122.24%
Unlock
2027
$697m 120.43%
Unlock
2028
$834m 19.56%
Unlock

2 Analysts have issued an Adagio Therapeutics Inc EBITDA forecast 2024. The average Adagio Therapeutics Inc EBITDA estimate is

$-193m
Unlock
. This is
17.29% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-187m 19.78%
Unlock
, the lowest is
$-198m 14.81%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-206m 15.38%
2024
$-193m 6.39%
Unlock
2025
$-58.2m 69.79%
Unlock
2026
$-22.7m 60.96%
Unlock
2027
$9.0m 139.61%
Unlock
2028
$50.6m 462.22%
Unlock

EBITDA Margin

2025
-40.89% 94.50%
Unlock
2026
-7.18% 82.44%
Unlock
2027
1.29% 117.97%
Unlock
2028
6.07% 370.54%
Unlock

4 Adagio Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Adagio Therapeutics Inc net profit estimate is

$-185m
Unlock
. This is
20.51% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-178m 23.59%
Unlock
, the lowest is
$-195m 16.41%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-216m 18.83%
2024
$-185m 14.36%
Unlock
2025
$-14.1m 92.42%
Unlock
2026
$63.4m 551.17%
Unlock
2027
$229m 261.30%
Unlock
2028
$269m 17.50%
Unlock

Net Margin

2025
-9.87% 98.62%
Unlock
2026
20.04% 303.04%
Unlock
2027
32.85% 63.92%
Unlock
2028
32.28% 1.74%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.81 -1.55
18.83% 14.36%
P/E negative
EV/Sales negative

4 Analysts have issued a Adagio Therapeutics Inc forecast for earnings per share. The average Adagio Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.55
Unlock
. This is
20.51% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.49 23.59%
Unlock
, the lowest is
$-1.63 16.41%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.81 18.83%
2024
$-1.55 14.36%
Unlock
2025
$-0.12 92.26%
Unlock
2026
$0.53 541.67%
Unlock
2027
$1.92 262.26%
Unlock
2028
$2.25 17.19%
Unlock

P/E ratio

Current -0.26 89.60%
2024
-0.33 26.92%
Unlock
2025
-4.34 1,215.15%
Unlock
2026
0.96 122.12%
Unlock
2027
0.27 71.88%
Unlock
2028
0.23 14.81%
Unlock

Based on analysts' sales estimates for 2024, the Adagio Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

-1.71
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -3.83
2024
-1.71 55.43%
Unlock
2025
-0.31 81.79%
Unlock
2026
-0.14 54.99%
Unlock
2027
-0.06 54.61%
Unlock
2028
-0.05 16.38%
Unlock

P/S ratio

Current
2024
2.35 55.40%
Unlock
2025
0.43 81.79%
Unlock
2026
0.19 54.99%
Unlock
2027
0.09 54.64%
Unlock
2028
0.07 16.34%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today